Follow Us
2023-2024
2022-2023
2021-2022
2020-2021
2019-2020
2018-2019
2017-2018
2016-2017
2015-2016
2014-2015
2013-2014
2012-2013
2011-2012
2010-2011
Addendum Notice
2009-2010
2008-2009
2007-2008
2006-2007
2005-2006 Part1
2005-2006 Part2
2004-2005 Part1
2004-2005 Part2
2003-2004 Part1
2003-2004 Part2
2002-2003
Alidac Healthcare (Myanmar) Limited
LM Manufacturing India Private Limited
Zydus Pharmaceuticals UK Limited
Zydus VTEC Limited
Zydus Worldwide DMCC
Zydus Lifesciences Global FZE
Zydus Animal Health And Investments Limited
Zydus Wellness Products Limited
Zydus Wellness International DMCC
Zynext Ventures USA LLC
Zynext Ventures PTE Limited
Zydus Wellness (BD) Pvt Limited
Zydus Wellness Limited
Zydus Therapeutics INC
Zydus Strategic Investments Limited
Zydus Pharmaceuticals Mexico Services Company SA De C.V.
Zydus Pharmaceuticals Mexico SA De CV
Zydus Pharmaceuticals Limited
Zydus Pharmaceuticals Canada Inc.
Zydus Pharmaceuticals (USA) Inc.
Zydus Nikkho Farmaceutica Ltda.
Zydus Netherlands B.V
Zydus Lanka Private Limited
Zydus International Private Limited
Zydus Healthcare S.A. (Pty) Ltd
Zydus Healthcare Philippines Inc.
Zydus Healthcare Limited
Zydus Healthcare (USA) LLC
Zydus France, SAS
Viona Pharmaceuticals (USA) Inc.
Violio Healthcare Limited
Sentynl Therapeutics Inc
Script Management Services (Pty) Ltd
Recon Pharmaceuticals and Investments
Medsolutions (Europe) Limited
LM Manufacturing Limited
Liva Nutritions Limited
Liva Investment Limited
LiqMeds Worldwide Limited
LiqMeds Limited
LiqMeds Lifecare Limited
Laboratorios Combix S.L.U.
German Remedies Pharmaceuticals Private Limited
Etna Biotech S.R.L
Dialforhealth Unity Limited
Dialforhealth Greencross Limited
Biochem Pharmaceutical Private Limited
Alidac Pharmaceuticals SA (Pty) Limited
Zydus Animal Health and Investments Limited
Zydus Worldwide DMCC
Zydus Wellness Products Limited
Zydus Wellness International DMCC
Zydus Wellness (BD) Pvt Limited
Zydus Wellness Limited
Zydus VTEC Limited
Zydus Therapeutics INC
Zydus Strategic Investments Limited
Zydus Pharmaceuticals Mexico Services Company SA De C.V.
Zydus Pharmaceuticals Mexico SA De CV
Zydus Pharmaceuticals Limited
Zydus Pharmaceuticals (USA) Inc.
Zydus Noveltech Inc.
Zydus Nikkho Farmaceutica Ltda.
Zydus Netherlands B.V
Zydus Lanka Private Limited
Zydus International Private Limited
Zydus Healthcare S.A. (Pty) Ltd
Zydus Healthcare Philippines Inc.
Zydus Healthcare Limited
Zydus Healthcare (USA) LLC
Zydus France, SAS
Viona Pharma INC
Violio Healthcare Limited
Simayla Pharmaceuticals (Pty) Ltd
Sentynl Therapeutics Inc
Recon Pharmaceuticals and Investments
Liva Nutritions Limited
Liva Investment Limited
Laboratorios Combix S.L.U.
Hercon Pharmaceuticals LLC
German Remedies Pharmaceuticals Private Limited
Etna Biotech S.R.L
Dialforhealth Unity Limited
Dialforhealth Greencross Limited
Biochem Pharmaceutical Private Limited
Alidac Healthcare (Myanmar) Limited
Script Management Services (Pty) Ltd
Sentynl Therapeutics, Inc
Alidac Healthcare (Myanmar) Limited
Simayla Pharmaceuticals (Pty) Ltd
Viona Pharma INC
Zydus France SAS
Zydus Healthcare (USA) LLC
Zydus Healthcare Philippines Inc.
Zydus Animal Health and Investments Limited
Zydus Lanka (Private) Limited
Zydus Netherlands BV
Zydus Nikkho Farmaceutica Ltda.
Zydus Noveltech Inc.
Zydus Pharmaceuticals (USA) Inc
Zydus Pharmaceuticals Mexico SA De CV
Zydus Pharmaceuticals Mexico Services Company SA De C.V.
Zydus Therapeutics Inc.
Zydus Wellness (BD) Pvt Limited
Zydus Healthcare S.A. (Pty) Ltd
Zydus Wellness International DMCC
Zydus Worldwide DMCC
Laboratorios Combix S.L.
DHGL
DHUL
GRPPL Audit Report
Violio Healthcare Limited
Zydus Healthcare Limited
Zydus Pharmaceuticals Limited
Biochem Pharmaceutical Private Limited
Zydus Strategic Investments Limited
Zydus International Private Limited
Zydus VTEC Limited
Script Management Services (Pty) Ltd
Recon Pharmaceuticals and Investments
Etna Biotech S.R.L.
Hercon Pharmaceuticals LLC
Dialforhealth Greencross Limited
Dialforhealth Unity Limited
Etna Biotech S.R.L.
German Remedies Pharmaceuticals Private Limited
Hercon Pharmaceuticals LLC
Laboratorios Combix S.L.
Liva Investment Limited
Liva Nutritions Limited
Script Management Services (Pty) Ltd
Sentynl Therapeutics, Inc.
Viona Pharmaceuticals (USA) Inc.
Zydus Discovery DMCC
Zydus France, SAS
Zydus Healthcare (USA) LLC
Zydus Healthcare Philippines Inc.
Zydus Healthcare S.A. (Pty) Ltd
Zydus International Private Limited
Zydus Lanka (Private) Limited
Zydus Netherlands B.V.
Zydus Nikkho Farmaceutica Ltda.
Alidac Healthcare (Myanmar) Limited
Simayla Pharmaceuticals (Pty) Ltd
Zydus Noveltech Inc.
Zydus Pharmaceuticals Limited
Zydus Pharmaceuticals Mexico SA De CV
Zydus Pharmaceuticals Mexico Services Company SA De C.V.
Zydus Strategic Investments Limited
Zydus VTEC Limited
Zydus Wellness International DMCC
Zydus Wellness Limited
Zydus Wellness Products Limited
Biochem Pharmaceutical Private Limited
Zydus Worldwide DMCC
Violio Healthcare Limited
Zydus Healthcare Limited
Zydus Pharmaceuticals (USA) Inc.
Zydus France SAS English Translated
Zydus Animal Health and Investments Limited
Etna Biotech SRL
Zydus Healthcare SA Pty Limited
Windlas Inc
Zydus International Private Limited
Zydus Lanka Private Limited
Zydus Pharmaceuticals USA Inc
Zydus Healthcare USA LLC
Sentynl Therapeutics Inc
Zydus France SAS
Zydus Healthcare Philippines Inc.
Viona Pharmaceuticals USA Inc
Hercon Pharmaceuticals LLC
Zydus Wellness International DMCC
Zydus Netherlands BV
Zydus Pharmaceuticals Mexico SA De CV
Script Management Services Pty Limited
Simayla Pharmaceuticals Pty Limited
Zydus Discovery DMCC
Alidac Healthcare Myanmar Limited
Windlas Healthcare Private Limited
Biochem Pharmaceutical Private Limited
Dialforhealth Unity Limited
Zydus Wellness Limited
Zydus Pharmaceuticals Limited
Liva Investment Limited
Liva Nutritions Limited
Zydus Nikkho Pharmaceutica Limitada
Zydus Wellness Products Limited.
Zydus Healthcare Limited
Zydus Takeda Audit Report March 2020
Zydus Takeda Financials
Zydus Hospira Oncology Private Limited
Laboratorios Combix SL
Zydus Noveltech Inc
Dialforhealth Greencross Limited
German Remedies Pharmaceuticals Private Limited
Zydus Pharmaceuticals Mexico Services Company SA De CV
Violio Healthcare Limited
Zydus Animal Health and Investments Limited
Zydus Nikkho Pharmaceutica Limitada
Zydus Pharmaceuticals USA Inc.
Zydus Noveltech Inc.
Zydus Pharmaceuticals Mexico Service Company SA de CV
Viona Pharmaceuticals Inc.
Zydus International Private Limited
Zydus Lanka Private Limited
Zydus Netherlands B. V.
Zydus Healthcare USA LLC
Laboratorios Combix SL
ZAHL BV
ZAHL Europe BV
Zydus Healthcare Philippines Inc
Zydus Healthcare SA Pty. Limited
Script Management Services Pty Limited
Sentynl Therapeutics Inc.
Zydus Discovery DMCC
Zydus France SAS
Dialforhealth Greencross Limited
Alidac Healthcare Myanmar Limited
Etna Biotech SRL
Dialforhealth Unity Limited
Dialforhealth India Limited
Alidac Pharmaceuticals Limited
Violio Pharmaceuticals Limited
Windlas Inc
Zydus Healthcare Limited
Windlas Healthcare Private Limited
Violio Healthcare Limited
Zydus Technologies Limited
Acme Pharmaceuticals Limited
Liva Pharmaceuticals Limited
Simayla Pharmaceuticals Pty. Limited
Zydus Wellness Limited
Liva Investment Limited
Zydus Nutritions Limited
Liva Nutritions Limited
Zydus Pharmaceuticals Mexico SA de CV
Zydus Worldwide DMCC
Zydus-Healthcare-Limited Mar18
Zydus Worldwide DMCC_Mar18
Zydus Wellness Limited_Mar18
Zydus Technologies Limited_Mar18
Zydus Pharmaceuticals Mexico Services Company SA De C.V._Dec17
Zydus Pharmaceuticals Mexico SA De CV_Dec17
Zydus Pharmaceuticals (USA) Inc Dec17
Zydus Noveltech Inc_Dec17
Zydus Nikkho Farmaceutica Ltda_Dec17
Zydus Netherland B.V _Dec17
Zydus Lanka Private Limited_Mar18
Zydus International Pvt. Ltd_Dec17
Zydus Healthcare S.A. (Pty) Ltd_Dec17
Zydus Healthcare (USA) LLC_Dec17
Zydus France_Dec17
Zydus Discovery DMCC_Mar18
ZAHL Europe BV_Mar18
ZAHL BV _Mar18
Simayla Pharmaceuticals (Pty) Ltd_Dec17
Sentynl Therapeutics Inc Dec17
Script Management Services Dec17
Liva Pharmaceuticals Limited Mar18
Hercon Pharmaceuticals LLC Dec17
Etna Biotech SRL Dec17
Dialforhealth Unity Limited Mar18
Dialforhealth India Limited Mar18
Dialforhealth Greencross Limited Mar18
Bremer Pharma GMBH Mar18
Alidac Pharmaceuticals Limited_Mar18
Alidac Healthcare (Myanmar) Limited Mar18
Zydus-Worldwide-DMCC 2016
Zydus-Pharmaceuticals-Mexico-Services-Company-SA-de-CV 2016
Zydus-Pharmaceuticals-Mexico-SA-de-CV 2016
Zydus-Noveltech-Inc 2016
Zydus-Netherlands-BV 2016
Zydus Lanka Private Limited 2016
Zydus International Private Limited 2016
Zydus Healthcare Limited Directors Report 2016
Zydus Healthcare Limited 2016
Simayla Pharmaceuticals SA Pty Limited 2016
Script-Management-Services-Pty-Limited 2016
Nesher-Pharmaceuticals-LLC 2016
Liva-Pharmaceuticals-Directors-Report-2016
Liva Pharmaceuticals Balance-Sheet 2016
Laboratorios Cmbix SL 2016
Hercon Pharmaceuticals LLC
Etna Biotech SRL
Dial for Health Unity Ltd 2016
Dial for Health India Ltd
Dial for Health Greencross Ltd 2016
Bremer Pharma GmbH 2016
Balance Sheet 2016
Alidac Healthcare Myanmar Limited 2016
LM Manufacturing India Private Limited
Zydus Lifesciences Limited
Zydus Wellness Products Limited
Zydus Wellness Limited
Zydus VTEC Limited
Zydus Strategic Investments Limited
Zydus Pharmaceuticals Limited
Zydus Healthcare Limited
Zydus Foundation
Zydus Animal Health and Investments Limited
Liva Nutritions Limited
Violio Healthcare Limited
Liva Investment Limited
Biochem Pharmaceutical Private Limited
Dialforhealth Unity Limited
Dialforhealth Greencross Limited
German Remedies Pharmaceuticals Private Limited
Zydus Lifesciences Limited
Biochem Pharmaceutical Private Limited
Dialforhealth Greencross Limited
Dialforhealth Unity Limited
German Remedies Pharmaceuticals Private Limited
Liva Investment Limited
Liva Nutritions Limited
Violio Healthcare Limited
Zydus Animal Health and Investments Limited
Zydus Foundation
Zydus Healthcare Limited
Zydus Pharmaceuticals Limited
Zydus Strategic Investments Limited
Zydus VTEC Limited
Zydus Wellness Limited
Zydus Wellness Products Limited
Zydus Wellness Products Limited
Zydus Wellness Limited
Zydus VTEC Limited
Zydus Strategic Investment Limited
Zydus Pharmaceuticals Limited
Zydus Lifesciences Limited
Zydus Healthcare Limited
Zydus Foundation
Zydus Animal Health and Investments Limited
Violio Healthcare Limited
Liva Nutritions Limited
Liva Investment Limited
German Remedies Pharmaceuticals Private Limited
Dialforhealth Unity Limited
Dialforhealth Greencross Limited
Biochem Pharmaceutical Private Limited
Zydus Pharmaceuticals limited
Cadila Healthcare Limited
Zydus Animal Health and Investments Limited
Zydus Wellness Products Limited
Zydus Wellness Limited
Zydus Strategic Investments Limited
Zydus Pharmaceuticaals Limited
Zydus Healthcare Limited
Violio Healthcare Limited
Liva Nutritions Limited
Liva Investment Limited
German Remedies Pharmaceuticals Private Limited
Dialforhealthe Unilty Limited
Dialforhealth Greencross Limited
Biochem Pharmaceutical Private Limited
Earnings call transcript 12-Nov-24 Q2 FY25 Earnings Call Intimation of Investor Call 12-Nov-2024 Earnings call transcript “09-Aug-2024 Audio Recording of Investor Call “09-Aug-202 Earnings call transcript 17-May-24 Audio Recording of Investor Call “17-May-2024 Earnings call transcript 09-Feb-24 Audio Recording of Investor Call “09-Feb-2024†Conference call on animal health business disposal | 12-May-2021 Earnings Call Transcript | 29-Oct-2021 Earnings Call Transcript | 11-Aug-2021 Earnings Call Transcript | 27-May-2021 Cadila Healthcare Limited Q3 FY21 Post results Conference Call Details | 05 February 2021 Earnings Call Transcript | 05-Feb-2021 CADILA HEALTHCARE Q2 2008-09 RESULTS CONFERENCE CALL OCTOBER 22 2008 CADILA HEALTHCARE Q2 2008-09 RESULTS CONFERENCE CALL OCTOBER 22 2008 CADILA HEALTHCARE Q3 2007-08 RESULTS CONFERENCE CALL JANUARY 31 2008 CADILA HEALTHCARE Q4 2007-08 RESULTS CONFERENCE CALL APRIL 30 2008 CADILA HEALTHCARE Q4 2007-08 RESULTS CONFERENCE CALL APRIL 30 2008 CADILA HEALTHCARE Q3 2007-08 RESULTS CONFERENCE CALL JANUARY 31 2008 CADILA HEALTHCARE Q2 2007-08 RESULTS CONFERENCE CALL OCTOBER 26 2007 CADILA HEALTHCARE Q2 2007-08 RESULTS CONFERENCE CALL OCTOBER 26 2007 CADILA HEALTHCARE Q1 2007-08 RESULTS CONFERENCE CALL JULY 31, 2007 (Audio format)31 July 2007 CADILA HEALTHCARE Q1 2007-08 RESULTS CONFERENCE CALL JULY 31, 2007 -31 July 2007 CADILA HEALTHCARE Q4 2006-07 RESULTS CONFERENCE CALL APRIL 26, 2007 (Audio format)26 April 2007 CADILA HEALTHCARE Q4 2006-07 RESULTS CONFERENCE CALL APRIL 26, 2007 -26 April 2007 CADILA HEALTHCARE Q3 2006-07 RESULTS CONFERENCE CALL JANUARY 22, 2007 -22 January 2007 CADILA HEALTHCARE Q3 2006-07 RESULTS CONFERENCE CALL JANUARY 22, 2007 -22 January 2007 CADILA HEALTHCARE Q2 2006-07 RESULTS CONFERENCE CALL OCTOBER 31, 2006 -31 October 2006 CADILA HEALTHCARE Q1 2006-07 RESULTS CONFERENCE CALL JULY 28, 2006 -28 July 2006 CADILA HEALTHCARE Q1 2006-07 RESULTS CONFERENCE CALL JULY 28, 2006 (Audio format)28 July 2006 CADILA HEALTHCARE Q4 2005-06 RESULTS CONFERENCE CALL CADILA HEALTHCARE Q4 2005-06 RESULTS CONFERENCE CALL CADILA HEALTHCARE Q3 2005-06 RESULTS CONFERENCE CALL CADILA HEALTHCARE Q3 2005-06 RESULTS CONFERENCE CALL CADILA HEALTHCARE Q2 2005-06 RESULTS CONFERENCE CALL CADILA HEALTHCARE Q2 2005-06 RESULTS CONFERENCE CALL CADILA HEALTHCARE Q1 2005-06 RESULTS CONFERENCE CALL CADILA HEALTHCARE Q1 2004-5 RESULTS CONFERENCE CALL CADILA HEALTHCARE Q1 2005-06 RESULTS CONFERENCE CALL CADILA HEALTHCARE Q1 2004-5 RESULTS CONFERENCE CALL CADILA HEALTHCARE Q3 2004-05 RESULTS CONFERENCE CALL CADILA HEALTHCARE Q3 2004-05 RESULTS CONFERENCE CALL Announcement of the consolidated Results of e.voting and Pole of 20th AGM (August 2015) Report on Pole Results of 20th AGM under Clause 35A of listing Agreement Scrutinizers Report on e.voting 20th AGM (August 2015) Public Notice in respect of 20th AGM 20th Annual General Meeting August 15 (Flash Presentation) Consolidated Report on Poll Results of e.voting and Pole of 19th AGM (Jul 2014) Announcement of the consolidated Results of e.voting and Pole of 19th AGM (Jul 2014) Report on Pole Results of 19th AGM under Clause 35A of listing Agreement Scrutinizers Report on e.voting 19th AGM (Jul 2014) 19th Annual General Meeting July 14 (Flash Presentation) Insider Trading Window Closure Intimation
List of shareholders whose dividend is transferred to unpaid dividend account
Loss of Share Certificate 22-Sep-2023
Update on acquisition of equity stake in Mylab-September 18, 2023
Loss of Share Certificate 11-Sep-2023
Incorporation of wholly owned subsidiary company in Canada
Amendment in Joint Venture Agreement entered into with Bayer (South East Asia) PTE Limited 27-Jul-2023
Loss of Share Certificate 26-Jul-2023
Disclosure of NCLT Order for merger of Pharmasofttech Awacs Private Limited into Pharmarack Technologies Private Limited 20-Jul-2023
Loss of Share Certificate 15-Jul-2023
Loss of Share Certificate 12-Jul-2023
Loss of Share Certificate 05-Jul-2023
Intimation of Outcome of EOGM 30-Dec-2022
Combined Results 30-Dec-2022
Transcript of 1st EOGM of FY 2022-23
Video Recording of EOGM 30-Dec-2022
Loss of Share Certificate 27-Dec-2022
Insider Trading Window Closure Intimation
Loss of Share Certificate 24-Dec-2022
List of Shareholders whose shares are liable to transfer to IEPF April 2023
Loss of Share Certificate 15-Dec-2022
Draft Letter of Appointment
Notice of EOGM 30-Dec-2022
Dialforhealth Greencross Limited Balance Sheet March 2015
Biochem Pharmaceuticals Industries Limited BalanceSheet March 2015
Zydus Worldwide DMCC Balance Sheet March 2015
Zydus-Pharma-Japan-Co-Ltd-BalanceSheet-March2015
Dialforhealth India Limited Balance Sheet March 2015
Dialforhealth Unity Limited Balance Sheet March 2015
German Remedies Limited Balance Sheet March 2015
Liva Pharmaceuticals Limited Balance Sheet March 2015
Zydus BSV Pharma Private Limited Balance Sheet March 2015
ETNA Biotech S.R.L Balance Sheet March 2015
Zydus Pharmaceuticals USA Inc. Balance Sheet December 2014
Zydus Netherlands B.V Balance Sheet December 2014
Zydus Pharmaceuticals Mexico S.A.De C.V. Accounts December 2014
Hercon Pharmaceuticals LLC Accounts December 2014
Zydus Noveltech Inc Accounts December 2014
Zydus International Private Limited Balance Sheet December 2014
Script Management Services Pty Ltd Balance Sheet December 2014
Zydus Pharmaceuticals Mexico Service Co. SA De C.V. Accounts December 2014
Simayla Pharmaceuticals Pty Ltd Balance Sheet December 2014
Nesher Pharmaceuticals USA LLC Accounts December 2014
Zydus France SAS Accounts December 2014
Zydus Healthcare USA LLC Balance Sheet December 2014
LABORATORIOS Combix S.L.U. Balance Sheet December 2014
Zydus Lanka private limited Balance Sheet March 2015
Zydus Healthcare Philippines INC Balance Sheet March 2015
Zydus Healthcare SA Pty Ltd Balance Sheet December2014
ZAHL Europe BV Balance Sheet March 2015
Zydus receives final approval from USFDA for Lidocaine and Prilocaine Cream USP, 2.5%/2.5% - 19/12/2024
Zydus Lifesciences Limited Financial Performance for Q2 & H1 FY25 - 12/11/2024
Press Release – 12/11/2024 - 12/11/2024
WHO prequalifies Zydus’s Typhoid Vi Conjugate Vaccine, ZyVac® TCV - 23/10/2024
Zydus receives final approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 mg - 17/10/2024
Zydus and ICMR initiate a Phase 2 proof-of-concept trial of Desidustat in patients with Sickle Cell Disease - 14/10/2024
Zydus receives final approval from USFDA for Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg - 10/10/2024
Zydus receives tentative approval from USFDA for Enzalutamide Tablets - 02/10/2024
Zydus receives final approval from USFDA for Enzalutamide Capsules, 40 mg - 28/09/2024
Zydus announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable, contrast agents in the US. - 13/09/2024
Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS) - 10/09/2024
Zydus receives final approval from USFDA for Scopolamine Transdermal System 1 mg/3 days - 30/08/2024
Zydus receives final approval from USFDA for Amantadine extended-release capsules 68.5 mg and tentative approval for 137 mg - 28/08/2024
Zydus to acquire 50% stake in Sterling Biotech from Perfect Day to enter into fermentation-based protein business - 23/08/2024
Zydus Lifesciences Limited Financial Performance for Q1 FY25 - 09/08/2024
Zydus receives final approval from USFDA for Valbenazine Capsules - 09/08/2024
Press Release – 09/08/2024 - 09/08/2024
Zydus receives approval from COFEPRIS of Mexico to market  Mamitra™ - 31/07/2024
Zydus receives final approval from USFDA for Valsartan Tablets - 23/07/2024
Zydus receives final approval from USFDA for its NDA ZituvimetTM XR (sitagliptin and metformin hydrochloride) extended-release tablets - 22/07/2024
Zydus receives approval from COFEPRIS of Mexico to market BhavaTM (Bevacizumab biosimilar) to treat various cancers - 22/07/2024
Zydus announces non-exclusive patent licensing agreement with Takeda for ‘Vault®’ (Vonoprazan) in India - 17/07/2024
Zydus receives tentative approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg - 10/07/2024
Zydus receives final approval from USFDA for Sacubitril and Valsartan Tablets - 10/07/2024
Zydus receives tentative approval from USFDA for Azilsartan Medoxomil Tablets, 40 mg and 80 mg - 04/07/2024
Zydus and Dr. Reddy’s announce licensing agreement for co- marketing of Pertuzumab biosimilar, a critical treatment for breast cancer patients in India - 03/07/2024
Zydus receives tentative approval from USFDA for Azilsartan Medoxomil and Chlorthalidone Tablets - 14/06/2024
Zydus Lifesciences announces completion of Enrolment for Phase II clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS) - 24/05/2024
Zydus receives final approval from USFDA for Theophylline Extended-Release Tablets, 300 mg and 450 mg - 22/05/2024
Zydus Lifesciences Limited Financial Performance for Q4 & Full Year FY24 - 17/05/2024
Press Release – 17/05/2024 - 17/05/2024
Zydus and MSN announces exclusive licensing and supply agreement for Cabozantinib Tablets (generic version of CABOMETYX®) for the US market - 17/05/2024
Zydus Wellness Ltd Q4 Net Sales up by 9.6% to Rs. 778 crores - 14/05/2024
Zydus receives final approval from USFDA for Dexamethasone Tablets USP, 1 mg - 11/05/2024
Zydus Announces Completion of Enrolment for EPICS IIITM Phase 2b/3 trial evaluating Saroglitazar Mg in treatment of Primary Biliary Cholangitis - 09/05/2024
Zydus receives final approval from USFDA for Dapsone Gel, 7.5% - 09/05/2024
Sentynl Therapeutics announces global acquisition of Zokinvy® (Lonafarnib) for treatment of Hutchinson-Gilford Progeria Syndrome from Eiger Biopharmaceuticals - 04/05/2024
Zydus receives final approval from USFDA for Tretinoin Cream USP, 0.1% - 26/04/2024
Inspection held at the Injectable Manufacturing site situated at Jarod, near Vadodara - 24/04/2024
New Drug Application of Zydus’ innovative drug Desidustat tablets by China Medical System Holdings Limited accepted in China - 23/04/2024
Zydus launches Mirabegron Extended-Release Tablets in the US - 22/04/2024
Sentynl Therapeutics receives marketing authorization for NULIBRY® (fosdenopterin) from the UK MHRA for treatment of MoCD Type A - 21/04/2024
Zydus Lifesciences receives approval for the name ‘Usnoflast’ as recommended name for ZYIL1 from the WHO International Non-proprietary Names (INN) - 01/04/2024
Zydus receives tentative approval from USFDA for Letermovir Tablets, 240 mg and 480 mg - 23/03/2024
Zydus receives final approval from USFDA and 180 days CGT exclusivity for Finasteride and Tadalafil Cap Capsules - 16/03/2024
Zydus receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials - 14/03/2024
Zydus receives Tentative Approval from the USFDA for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), Single-Dose Vial - 14/03/2024
Zydus launches IBYRA, the generic version of Olaparib, brings both access and affordability for cancer patients in India - 13/03/2024
Zydus receives EIR for the API Ahmedabad facility - 10/03/2024
Zydus receives Post Application Action Letter for the USFDA cGMP nd Pre-Approval Inspection (PAI) at the Ahmedabad API facility - 07/03/2024
Zydus receives WHO prequalification for Miltefosine formulation and API - 27/02/2024
Zydus receives Final Approval from the USFDA for Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg - 16/02/2024
Zydus receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg - 09/02/2024
Press Release - 09/02/2024
Zydus receives Final Approvals from the USFDA for Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg and Dexamethasone Tablets USP, 2 mg - 08/02/2024
Zydus receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 mg and 600 mg - 30/01/2024
Zydus Lifesciences launches Rexigoâ„¢, the oral once-a-day pill for advanced prostate cancer patients in India - 30/01/2024
Zydus and Synthon enter into an exclusive licensing and supply agreement for Palbociclib Tablets (generic version of IBRANCE ® ) for the US market - 18/01/2024
Zydus receives Final Approvals from the USFDA for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg - 17/01/2024
Zydus receives final approval from the USFDA for Lacosamide Tablets - 16/12/2023
Zydus receives approval from USFDA to initiate Phase II clinical trial of ZYIL1 in patients with Parkinson’s disease - 16/12/2023
Zydus receives final approval from the USFDA for Darunavir Tablets 600 mg and 800 mg, and tentative approval for 75 mg and 150 mg tablets - 15/12/2023
Zydus receives final approval from the USFDA for Cyclophosphamide Capsules USP, 25 mg and 50 mg - 14/12/2023
Zydus and Daewoong Pharmaceutical announce exclusive licensing agreement for development and commercialization of Leuprolide Long-Acting Injectable in the U.S. - 14/12/2023
Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics - 06/12/2023
Zydus receives Final Approval from the USFDA for Methylene Blue Injection - 06/12/2023
Zydus receives final approval from the USFDA for Ivabradine Tablets, 5 mg and 7.5 mg - 01/12/2023
Zydus and Torrent sign licensing agreement for co-marketing Saroglitazar Mg, a critical treatment for chronic liver diseases in India - 10/11/2023
Press Release – 07/11/2023 - 07/11/2023
Zydus receives USFDA approval for ZITUVIMETTM to treat adult patients with type 2 diabetes mellitus - 06/11/2023
Zydus and Lupin sign licensing agreement for co-marketing Saroglitazar Mg, a critical treatment for chronic liver diseases in India - 03/11/2023
Zydus and Guardant Health to jointly promote the Guardant360® portfolio of next-generation genomic tests for advanced solid cancers in India and Nepal - 02/11/2023
Zydus acquires UK based LiqMeds® Group – 31/10/2023 - 31/10/2023
Zydus and Sun Pharma sign licensing agreement for co-marketing of Desidustat, a critical treatment for Chronic Kidney Disease patients in India - 30/10/2023
Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS) - 25/10/2023
Zydus receives USFDA approval for ZITUVIOTM to treat adult patients with type 2 diabetes mellitus - 21/10/2023
Zydus announces IND clearance of a novel Anti-PCSK9 candidate - 29/09/2023
Zydus receives final approval from the USFDA for Clindamycin Phosphate Gel USP, 1% - 20/09/2023
Zydus receives EIR for the formulation manufacturing facility at SEZ 2, Ahmedabad - 19/09/2023
Zydus receives final approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day - 15/09/2023
Zydus receives EIR for the injectables manufacturing facility at Zydus Biotech Park, Ahmedabad - 13/09/2023
Zydus receives final approval from the USFDA for Erythromycin Tablets USP, 250 mg and 500 mg - 01/09/2023
Zydus receives final approval from the USFDA for Isotretinoin Capsules USP, 10 mg, 20 mg 30 mg and 40 mg - 31/08/2023
Zydus to present on ZYIL1 at the International Congress of Parkinson’s Disease and Movement Disorders - 25/08/2023
Zydus receives final approval from the USFDA for Zinc Sulfate Injection USP, 10 mg/10 mL (1 mg/mL), 30 mg/10 mL (3 mg/mL), and 25 mg/5 mL (5 mg/mL) Pharmacy Bulk Package Vials - 24/08/2023
Press Release - 11/08/2023
Zydus Wellness posts Net Sales of Rs. 699 crores in Q1 - 03/08/2023
Zydus receives Final Approval from the USFDA for Indomethacin Suppository with Competitive Generic Therapy (CGT) designation - 03/08/2023
Zydus receives final approval from the USFDA for Plerixafor Injection USP, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial - 27/07/2023
Zydus receives final approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg - 04/07/2023
Zydus receives tentative approval from the USFDA for Palbociclib Tablets, 75 mg, 100 mg, and 125 mg - 28/06/2023
Zydus receives final approval from the USFDA for Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg - 19/06/2023
USFDA inspection at Zydus’ injectables manufacturing facility at Zydus Biotech Park, concludes with Nil observations - 14/06/2023
Zydus receives final approval from the USFDA for Varenicline Tablets - 13/06/2023
Zydus receives final approval from the USFDA for Diclofenac Sodium and Misoprostol Delayed Release Tablets - 13/06/2023
Zydus receives final approval from the USFDA for Balsalazide Disodium Capsules USP, 750 mg - 10/06/2023
Zydus announces Phase IV EVIDENCES-XI trial to generate Real World Evidence of Saroglitazar Mg in Non-Alcoholic Fatty Liver Disease (NAFLD) patients with comorbidities - 09/06/2023
Zydus receives final approval from the USFDA for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg - 08/06/2023
Zydus receives final approval from the USFDA for Tadalafil Tablets USP, 20 mg - 07/06/2023
Zydus Lifesciences Limited Reports Financial Performance for Q4 and Full Year FY23 - 18/05/2023
Zydus receives final approval from the USFDA for Ephedrine Sulfate Injection - 17/05/2023
Zydus receives final approval from the USFDA for Sucralfate Tablets USP, 1 gram - 04/05/2023
Zydus receives final approval from the USFDA for Metronidazole Topical Cream, 0.75% - 26/04/2023
Zydus receives final approval from the USFDA for Icosapent Ethyl Capsules, 0.5 g and 1 g - 24/04/2023
Zydus receives final approval from the USFDA for Metoprolol Tartrate Tablets USP, 25 mg, 50 mg, and 100 mg - 20/04/2023
Zydus receives final approval from the USFDA for Roflumilast Tablets, 250 mcg - 19/04/2023
Zydus receives final approval from the USFDA for Estradiol Transdermal System - 18/04/2023
Zydus receives final approval from the USFDA for Isoproterenol Hydrochloride Injection - 15/04/2023
Zydus receives final approval from the USFDA for Tavaborole Topical Solution, 5% - 11/04/2023
Zydus receives final approval from the USFDA for Azithromycin Tablets USP, 500 mg - 10/04/2023
Zydus receives final approval from the USFDA for Carbidopa and Levodopa Tablets USP, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg - 06/04/2023
Zydus receives final approval from the USFDA for Acetazolamide Tablets USP, 125 mg and 250 mg - 06/04/2023
Zydus receives Final Approval from the USFDA for Doxepin Hydrochloride Capsules - 28/03/2023
Zydus receives Final Approval from the USFDA for Levothyroxine Sodium for Injection - 28/03/2023
Zydus receives Final Approval from the USFDA for Loperamide Hydrochloride Capsules USP, 2 mg - 28/03/2023
Zydus receives Final Approval from the USFDA for Lubiprostone Capsules, 8 mcg and 24 mcg - 24/03/2023
Zydus receives final Approval from the USFDA for Doxepin Hydrochloride Capsules USP, 150 mg - 24/03/2023
Zydus granted Orphan Drug Designation by the USFDA for ZYIL1 in treatment of patients with Cryopyrin Associated Periodic Syndrome (CAPS) - 21/03/2023
Zydus receives final and tentative Approval from the USFDA for Tofacitinib Tablets, 5 mg and 10 mg, respectively - 21/03/2023
Zydus receives final approval from the USFDA for Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10 mg, 15 mg, and 20 mg - 11/03/2023
Zydus receives final approval from the USFDA for Erythromycin Tablets USP, 250 mg and 500 mg - 09/03/2023
Zydus receives final approval from the USFDA for Lenalidomide Capsules, 2.5 mg and 20 mg - 07/03/2023
Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution USP, 500 mg - 03/03/2023
Zydus receives final approval from the USFDA for Acyclovir Cream - 02/03/2023
Zydus receives final approval from the USFDA for Olmesartan Medoxomil and Hydrochlorothiazide Tablets - 28/02/2023
Zydus receives final approval from the USFDA for Apixaban Tablets, 2.5 mg and 5 mg - 28/02/2023
Zydus receives tentative approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 mg and 600 mg - 20/02/2023
Zydus receives tentative approval from the USFDA for Canagliflozin and Metformin Hydrochloride Tablets - 20/02/2023
Zydus receives final approval from the USFDA for Sirolimus Tablets - 17/02/2023
Zydus receives tentative approval from the USFDA for Bosentan Tablets for Oral Suspension - 15/02/2023
Zydus receives tentative approval from the USFDA for Canagliflozin Tablets - 15/02/2023
Zydus receives tentative approval from the USFDA for Levomilnacipran Extended-Release Capsules - 16/01/2023
Zydus receives final approval from the USFDA for Febuxostat Tablets - 10/01/2023
Zydus receives final approval from the USFDA for Triazolam Tablets - 30/12/2022
Zydus receives final approval and 180 days shared exclusivity from the USFDA for Selexipag Tablets - 22/12/2022
Zydus receives two final approvals from the USFDA for Silodosin capsules and Pregabalin capsules - 10/12/2022
Zydus receives final approval from the USFDA for Estradiol Transdermal System which will be manufactured at the Moraiya plant - 02/12/2022
Zydus receives final approval from the USFDA for Topiramate Extended-Release Capsules - 01/12/2022
Zydus receives tentative approval from the USFDA for Levothyroxine Sodium for Injection - 28/11/2022
Zydus receives final approval from the USFDA for Famotidine Injection - 23/11/2022
Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast- an innovative prognostic test for breast cancer patients - 16/11/2022
Zydus receives final approval from the USFDA for Bisoprolol Fumarate and Hydrochlorothiazide Tablets - 08/11/2022
Zydus receives EIR with Voluntary Action Indicated (VAI) from USFDA for its Moraiya formulations manufacturing facility - 07/11/2022
Zydus Announces New Data Presentations at The Liver Meeting 2022 - 03/11/2022
Zydus receives final approval from the USFDA for Acetaminophen Injection - 29/10/2022
Zydus receives final approval from the USFDA for Micafungin for Injection - 26/10/2022
Zydus receives final approval from the USFDA for Ketorolac Tromethamine Tablets - 22/10/2022
Zydus receives tentative approval from the USFDA for Amantadine Extended-Release Capsules - 04/10/2022
Zydus receives final approval from USFDA and 180 days shared exclusivity for Mirabegron Extended-Release Tablets - 03/10/2022
Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension - 01/10/2022
BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A - 20/09/2022
Zydus launches Lenalidomide Capsules - 20/09/2022
Zydus receives tentative approval from the USFDA for Sugammadex Injection - 16/09/2022
Zydus receives final approval from the USFDA for Lenalidomide Capsules 5 mg, 10 mg, 15 mg and 25 mg - 13/09/2022
Zydus receives final approval and 180 days shared exclusivity from the USFDA for Cariprazine Capsules - 12/09/2022
Zydus in-licenses a critical drug for CKD patients from Pharmacosmos of Denmark - 09/09/2022
Zydus announces positive Phase 2 Proof-of-Concept of NLRP3 inhibitor, ZYIL1 in patients with Cryopyrin Associated Periodic Syndrome (CAPS) - 07/09/2022
Zydus receives two final approvals from the USFDA - 31/08/2022
Zydus announces Phase IV DREAM-CKD trial to generate Real World Evidence of Desidustat in patients with Chronic Kidney Disease induced anemia - 30/08/2022
Zydus receives final approval from the USFDA for Prochlorperazine Maleate Tablets - 11/08/2022
Zydus Lifesciences Limited Financial Performance for Q1 FY23 - 10/08/2022
Zydus Receives Final Approval From The USFDA For Ivermectin Cream - 04/08/2022
Zydus Receives Final Approval From The USFDA For Empagliflozin Tablets - 04/08/2022
Zydus receives final approval from the USFDA for Bisoprolol Fumarate Tablets - 26/07/2022
Zydus receives final approval from the USFDA for Norepinephrine Bitartrate Injection - 21/07/2022
Zydus receives final approval from the USFDA for Empagliflozin and Metformin Hydrochloride Tablets - 11/07/2022
Zydus has launched Sitaglyn and Siglyn (Sitagliptin), for the management of Type 2 diabetes - 08/07/2022
Zydus Lifesciences receives final approval from USFDA for Adapalene and Benzoyl Peroxide Topical Gel - 07/06/2022
Press Release Zydus Lifesciences receives final approval from USFDA for Famotidine Tablets - 06/06/2022
Press Release Zydus receives EIR from USFDA for its injectables manufacturing facility at Jarod - 27/05/2022
Zydus receives final approval to market Pemetrexed for Injection 2 - 26/05/2022
Zydus Lifesciences Limited Reports Financial Performance for Q4 FY22 and Full Year FY22 - 20/05/2022
Zydus Lifesciences Limited Reports Financial Performance for Q4 FY22 and Full Year FY22 - 20/05/2022
Zydus announces the launch of Bemdac for the first time in India to treat uncontrolled LDL-Cholesterol - 13/05/2022
Zydus announces the launch of Bemda for the first time in India to treat uncontrolled LDL-Cholesterol - 13/05/2022
Zydus receives tentative approval from USFDA for Selexipag Tablets - 06/05/2022
Zydus Lifesciences receives tentative approval from USFDA for Selexipag tablets - 06/05/2022
Zydus receives final approval from USFDA for Bortezomib for Injection - 03/05/2022
Zydus Lifesciences receives final approval from USFDA for Bortezomib for Injection - 03/05/2022
ZyCoV-D as a two-dose vaccine receives EUA from DCGI - 26/04/2022
Zydus announces publication of DREAM-ND and DREAM-D Phase 3 trials of Desidustat in American Journal of Nephrology - 25/04/2022
Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection - 18/04/2022
Zydus to supply Sagents Caffeine Citrate Oral Solution from Jarod, post USFDAs PAS Approval - 13/04/2022
The Lancet publishes Phase III data of ZyCoV-D - 01/04/2022
Zydus receives Prior Approval Supplement (PAS) approval from USFDA for Mycophenolate Mofetil for Injection USP - 21/03/2022
Fortress Biotech and Cyprium Therapeutics alongwith Zydus Sentynl Therapeutics Announce CUTX-101, Copper Histidinate Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting - 21/03/2022
Zydus receives final approval from USFDA for Colestipol Hydrochloride Tablets - 14/03/2022
Zydus receives final approval from USFDA for Colestipol Hydrochloride Tablets - 09/03/2022
Sentynl Therapeutics Inc., a wholly owned subsidiary of Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) and BridgeBio Pharma Announce Asset Purchase Agreement for BridgeBio Pharmas NULIBRYTM (Fosdenopterin) - 08/03/2022
Zydus to launch Oxemia (Desidustat) a breakthrough treatment for Anemia in patients suffering from Chronic Kidney Disease (CKD) - 07/03/2022
Cadila Healthcare Limited is now Zydus Lifesciences Limited - 24/02/2022
Zydus gets final approval for Dapagliflozin Tablets - 24/02/2022
Zydus gets 180 days shared exclusivity for Roflumilast Tablets - 15/02/2022
Zydus posts consolidated revenues of Rs. 3655 crores in Q3 - 03/02/2022
Zydus supplies the first consignment of its COVID-19 vaccine ZyCoV-D - 02/02/2022
Zydus Wellness registers net sales of Rs.3,849 mn and net profit of Rs.233 mn in Q3 - 02/02/2022
Zydus receives final approval from USFDA for Vigabatrin Tablets - 20/01/2022
Zydus Cadila receives tentative approval from USFDA for Pimavanserin Tablets - 22/12/2021
Zydus receives Orphan Drug Designation from US FDA for ZY-19489, a novel compound to treat malaria - 16/12/2021
Zydus to begin Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with CryopyrinAssociated Periodic Syndrome (CAPS) in Australia - 13/12/2021
Zydus announces EPICS-IIITM Phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in PBC - 10/12/2021
Zydus Cadila receives tentative approval from USFDA for Cariprazine Capsules - 10/12/2021
Together We Fly Quilt Press Note - 06/12/2021
Zydus develops new treatment for patients suffering from Chronic Kidney Disease (CKD), submits first New Drug Application (NDA) to DCGI - 23/11/2021
Zydus Cadila gets 180-day exclusivity for Nelarabine injection, announces final approval from USFDA - 18/11/2021
Zydus Cadila receives final approval from USFDA for Glycopyrrolate Injection - 10/11/2021
Cadila Healthcare Ltd., to supply 1 crore doses of ZyCoV-D, the worlds first Plasmid DNA vaccine to the Government of India - 08/11/2021
Zydus Cadila posts consolidated revenues of Rs. 3785 crores in Q2 - 29/10/2021
zydus announces first patient randomised in EVIDENCES-X TM Phase II(b) clinical trial of Saroglitazar Mg in NASH - 22/10/2021
Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate - 08/10/2021
Zydus Cadila receives tentative approval from USFDA for Adapalene and Benzoyl Peroxide Gel - 08/10/2021
Zydus Cadila receives final approval from USFDA for Apremilast Tablets - 24/09/2021
Zydus Cadila receives final approval from USFDA for Vortioxetine Tablets - 18/09/2021
Zydus Cadila receives tentative approval from USFDA for Brexpiprazole Tablets - 09/09/2021
Zydus Cadilas Sitagliptin Base Tablets Receives Tentative Approval from FDA - 06/09/2021
Zydus Cadila gets 180-day exclusivity for Tofacitinib extendedrelease 22 mg tablets, announces final approval from USFDA - 23/08/2021
Zydus Receives EUA from DCGI for ZyCoV-D - 20/08/2021
Zydus partners with CHEMI of Italy to launch Enoxaparin Sodium Injection in the United State - 20/08/2021
Zydus Cadila receives tentative approval from USFDA for Lenalidomide Capsules - 17/08/2021
Zydus Cadila receives final approval from USFDA for Mesalamine Extended-Release Capsules - 13/08/2021
Zydus Cadilas Q1 Net Profit up by 29% - 11/08/2021
Zydus Cadila receives tentative approval from the USFDA for Ibrutinib Tablets - 21/07/2021
European Medicines Agency grants Orphan Drug Designation to Saroglitazar Mg for the treatment of patients with Primary Biliary Cholangitis (PBC) - 21/07/2021
Zydus applies to the DCGI for EUA to launch ZyCoV-D, the worlds first Plasmid DNA vaccine for COVID-19 - 01/07/2021
Zydus Cadila receives tentative approval from USFDA for Pemetrexed for Injection - 25/06/2021
Zydus Cadila receives tentative approval from USFDA for Fingolimod Capsules .25mg - 24/06/2021
Zydus and Bayer announce continuity of their successful Joint Venture - 21/06/2021
Zydus Cadila receives tentative approval from USFDA for Brivaracetam Tablets - 14/06/2021
Zydus Cadila receives tentative approval from USFDA for Osimertinib Tablets - 03/06/2021
Zydus new tech enabled initiative to safeguard patients against counterfeit drugs - 28/05/2021
Zydus seeks DCGI approval to undertake clinical trials for monoclonal antibodies cocktail that can neutralise COVID infection - 27/05/2021
Zydus Cadilas EBIDTA crosses mark of Rs. 30 bn - 27/05/2021
Zydus and TLC sign agreement to market Liposomal Amphotericin B, a critical drug to treat Black Fungus or Mucormycosis in India - 26/05/2021
Zydus Launches Ujvira (Trastuzumab Emtansine), a Breakthrough in Breast Cancer Treatment - 24/05/2021
Zydus Cadila entity to sell its India focused Animal Health Business to Multiples Alternate Asset Management led consortium - 12/05/2021
Zydus Wellness consolidated Q4 Net Profit up by 92.7% at Rs. 1331 million - 10/05/2021
Zydus receives Emergency Use Approval from DCGI for the use of Pegylated Interferon alpha-2b, Virafin in treating moderate COVID-19 infection in adults - 23/04/2021
Zydus Cadila receives final approval from USFDA for Propafenone Hydrochloride Extended Release Capsules - 23/04/2021
Zydus Cadila receives final approval from the USFDA for Ibrutinib Capsules - 08/04/2021
Zydus Cadila announces final USFDA approval for Macitentan Tablets, 10 mg and gets eligibility for 180-day shared exclusivity - 08/04/2021
Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19 - 05/04/2021
Zydus Cadila receives tentative approval from the USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets - 25/03/2021
Zydus Announces Settlement of Patent Litigation for Generic Revlimid in U.S - 24/03/2021
Remdac (Remdesivir) from Zydus now more affordable at Rs. 899 - 24/03/2021
Zydus Cadila receives final approval from USFDA for Nortriptyline Hydrochloride Capsules - 25/02/2021
Sentynl Therapeutics Asset Purchase Agreement for Cyprium Therapeutics Copper Histidinate Product Candidate for Treatment of Menkes Disease - 24/02/2021
Zydus Cadila receives final approval from USFDA for Droxidopa Capsules - 19/02/2021
Zydus completes large scale enrolment for two Phase III trials of Desidustat - 05/02/2021
Zydus Cadilas Net Profit up by 41% in Q3 FY21 - 05/02/2021
Zydus announces completion of Phase-I trials of ZY19489A single dose cure for Malaria in collaboration with MMV - 04/02/2021
zydus Wellness registers consolidated net sales of Rs, 3,764 million in Q3, up by 15.6% - 01/02/2021
Zydus granted Orphan Drug Designation by the USFDA for Saroglitazar in the treatment of patients with Primary Biliary Cholangitis (PBC) - 28/01/2021
Zydus Desidustat shows efficacy and safety in treating Hypoxia in hospitalized Covid-19 patients in Mexico - 25/01/2021
Zydus Cadila receives final approval from USFDA for Liothyronine Sodium Tablets - 23/01/2021
Zydus Cadila receives approvals from the DCGI to start Phase III Clinical Trial of ZyCoV-D fully indigenously developed vaccine - 03/01/2021
Zydus announces the approval of Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease in India - 30/12/2020
Zydus Cadila submits Phase I/II clinical trial data of ZyCoV-D, seeks nod to start Phase III Clinical Trials - 24/12/2020
Zydus granted Fast Track Designation by the USFDA for Saroglitazar in the treatment of patients with Primary Biliary Cholangitis (PBC) - 09/12/2020
Zydus announces Phase I trials of ZYIL1, a novel oral small molecule NLRP3 inflammasome inhibitor - 07/12/2020
Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India - 04/12/2020
Hon'ble Prime Minister of India, Shri Narendra Modijis inspiring presence at the Zydus Biotech Park - 28/11/2020
Zydus successfully completes Phase II clinical trials with Pegylated Interferon alpha2b in India; the Company to start Phase III clinical trials - 12/11/2020
Zydus announces IND filing of ZYIL1, a novel oral small molecule NLRP3 inflammasome inhibitor - 03/11/2020
Zydus to present PBC and NASH clinical trial data of Saroglitazar Mg at the AASLDs The Liver Meeting Digital Experience 2020 - 02/11/2020
Zydus Cadila Consolidated Profits Jump 73% in Q2 - 02/11/2020
Zydus Wellness Ltd posts Total Income From Operations Of Rs 3420 mn in Q2 - 02/11/2020
Zydus Cadila receives tentative approval from USFDA for Dapagliflozin Tablets - 29/10/2020
Zydus Cadila receives final approval from USFDA for Albuterol Tablets - 23/10/2020
Zydus Cadila receives Final Approval from USFDA for Solifenacin Succinate Tablets - 20/10/2020
Zydus Cadila receives tentative approval from USFDA for Tofacitinib Extended-Release Tablets - 19/10/2020
Zydus Cadila receives Final Approval from USFDA for Ursodiol Capsules and Tentative Approval for Linagliptin and Metformin Hydrochloride Tablets - 18/10/2020
Zydus Cadila receives final approval from USFDA for Fingolimod Capsules and Verapamil Hydrochloride Injection - 16/10/2020
Zydus launches Indias first pressurized Metered Dose Inhaler for patients suffering from Chronic Obstructive Pulmonary Disease - 08/10/2020
Zydus Healthcare launches highly affordable Dapagliflozin tablets in India for the treatment of Type 2 diabetes - 04/10/2020
Zydus Cadila receives final approval for Dimethyl Fumarate Delayed Release Capsules - 25/09/2020
Zydus Cadila receives tentative approval from USFDA for Palbociclib Capsules - 24/09/2020
Zydus Cadila receives final approval from USFDA for Potassium Chloride Extended-Release Tablets - 18/09/2020
Zydus Cadila receives its first complex injectable approval from USFDA for Doxorubicin Hydrochloride Liposome Injection - 11/09/2020
Zydus Cadila receives final approval from the USFDA to market Midodrine Hydrochloride Tablets - 03/09/2020
Zydus Cadila receives final approval from the USFDA for Cisatracurium Besylate Injection - 02/09/2020
Zydus Cadila receives final approval from the USFDA for Sevelamer Carbonate Tablets - 13/08/2020
Zydus launches RemdacTM (Remdesivir) for the treatment of COVID 19 in India - 13/08/2020
Zydus Cadila's Q1 Net profit up by 50% - 05/08/2020
Zydus Cadila announces completion of dosing in Phase I clinical trial of ZyCoV-D - 05/08/2020
Zydus Cadila receives tentative approval from the USFDA for Carbidopa and Levodopa Extended-Release Capsules - 01/08/2020
Zydus receives approval from USFDA to initiate clinical trials of Desidustat in Cancer Patients receiving Chemotherapy - 23/07/2020
Zydus Cadila receives final approval from USFDA for Butalbital, Acetaminophen and Caffeine Tablets - 18/07/2020
Zydus Cadila receives final approval from USFDA for Butalbital, Acetaminophen and Caffeine Tablets - 18/07/2020
Zydus receives approval from COFEPRIS to conduct clinical trials in Mexico with Pegylated Interferon alpha-2b to treat novel Coronavirus - 17/07/2020
Zydus receives approval from COFEPRIS to conduct clinical trials in Mexico with Pegylated Interferon alpha-2b to treat novel Coronavirus - 17/07/2020
Zydus Cadila receives final approval from USFDA for Betamethasone Dipropionate Ointment - 15/07/2020
Zydus Starts Human dosing of its Vaccine ZyCoV-D - 15/07/2020
Zydus receives approval from COFEPRIS, Mexico to study Desidustat in the management of COVID-19 - 06/07/2020
Zydus vaccine for COVID-19 (ZyCoV-D) successfully completes preclinical development and receives permission to initiate human clinical trials - 03/07/2020
Zydus Cadila receives final approval from USFDA for Meclizine Hydrochloride Tablets - 24/06/2020
Zydus Cadilas Q4 operating profits up by 13% on a sequential basis - 19/06/2020
Zydus Cadila receives final approval from USFDA for Deferasirox Tablets - 16/06/2020
Zydus signs a non-exclusive licensing agreement with Gilead Sciences - 12/06/2020
Zydus Cadila receives final approval from USFDA for Atazanavir Capsules - 05/06/2020
Zydus Wellness posts growth of 112.5% in Total Income in FY 20 - 02/06/2020
Zydus supplies COVID KAVACH ELISA kits to ICMR - 21/05/2020
Zydus Cadila receives tentative approval from USFDA for Droxidopa Capsules, 100 mg, 200 mg, and 300 mg - 16/05/2020
Zydus Cadila Launches Enzalutamide, making Prostate Cancer therapy highly affordable - 08/05/2020
Zydus Cadila receives final approval from USFDA for Deferasirox Tablets for Oral Suspension - 07/05/2020
Zydus receives tentative approval from USFDA for Empagliflozin and Metformin Hydrochloride Tablets - 02/05/2020
Zydus explores the biologicals route to treat novel Coronavirus with long-acting Interferon alpha-2b - 20/04/2020
Zydus receives final approval from USFDA for Baclofen Tablets - 18/04/2020
Zydus receives final approval from USFDA for Erlotinib Tablets - 17/04/2020
Zydus receives tentative approval from the USFDA for Macitentan Tablets - 15/04/2020
Zydus receives tentative approval from the USFDA for Empagliflozin Tablets - 10/04/2020
Zydus receives final approval from USFDA for Imatinib Mesylate Tablets - 09/04/2020
Zydus receives final approval from USFDA for Perphenazine Tablets USP - 07/04/2020
Zydus receives final approval from the USFDA for Lamotrigine Extended-Release Tablets - 02/04/2020
Zydus receives tentative approval from the USFDA for Carbidopa and Levodopa Extended-Release Capsules - 30/03/2020
Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement - 09/03/2020
Zydus announces worlds first drug for the treatment of Non-Cirrhotic NASH - 05/03/2020
Zydus receives final approval from the USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg - 04/03/2020
Zydus receives Phase I clinical trial permission for ZYBK2 from DCGI - 03/03/2020
Zydus Cadila launches a fast tracked programme to develop vaccine for the novel coronavirus, 2019-nCoV (COVID-19) - 15/02/2020
Zydus receives final approval from the USFDA for Mesalamine Suppositories for rectal use, 1000 mg - 13/02/2020
Zydus receives final approval from the USFDA for Fluocinonide Cream USP, 0.1%. - 11/02/2020
Zydus Cadilas Net Profit up by 18%in Q3 on a sequential basis - 05/02/2020
Zydus receives approval from DCGI for Saroglitazar Magnesium for treatment of Type II Diabetes - 03/02/2020
Zydus and China Medical System Holdings enter into a License Agreement for Desidustat in Greater China - 20/01/2020
Vinglyn - 11/12/2019
Zydus announces NDA filing of Saroglitazar Magnesium with DCGI for treatment of NASH - 05/12/2019
Zydus receives tentative approval from the USFDA for Lorcaserin Hydrochloride Tablets - 03/12/2019
Zydus receives final approvals from the USFDA for Isosorbide Dinitrate Tablets and Desonide Cream - 21/11/2019
Desidustat Trials - 18/11/2019
Zydus receives tentative approval from the USFDA for Apremilast Tablets - 16/11/2019
Zydus Cadila registers Total income from Operations - 13/11/2019
Zydus receives final approval from the USFDA for Cisatracurium Besylate Injection USP - 05/11/2019
Liva Pharmaceuticals receives approval from the USFDA for Haloperidol Decanoate Injection - 24/10/2019
EVIDENCES IV presentation at AASLD - 23/10/2019
API Dabhasa zero 483 - 11/10/2019
Zydus receives final approval from the USFDA for Colesevelam Hydrochloride Tablets - 09/10/2019
EVIDENCES IV Saroglitazar NAFLD and NASH - 02/10/2019
Zydus receives final approval from the USFDA for Clobetasol Propionate Lotion - 26/09/2019
Zydus to Launch Novel Biologic for Rabies - 03/09/2019
NASH & PCOS - 21/08/2019
Zydus receives final approval from the USFDA for Ranolazine Extended-Release Tablets - 21/08/2019
Zydus Cadila registers Total income from Operations - 09/08/2019
Zydus Announces Completion of Phase III trials of Saroglitazar Magnesium in Type 2 Diabetes Mellitus - 02/08/2019
Zydus has launched Ramelteon Tablets in the US upon receiving final approval from the USFDA - 24/07/2019
Zydus Nesher Pharmaceuticals receives final approval from the USFDA - 19/07/2019
Press Release Evidences II III V India Mexico - 18/07/2019
Misoprostol Tablets - 03/07/2019
USFDA for Omega-3-Acid Ethyl Esters Capsules - 15/06/2019
Zydus Cadilas total income from operations up by 15% in Q4 - 29/05/2019
Zydus receives Final approval from the USFDA for Esomeprazole Magnesium Delayed-Release Capsules USP - 23/05/2019
Zydus receives Final approval from the USFDA for Chlorthalidone Tablets - 13/05/2019
Zydus receives final approval from the USFDA for Bosentan Tablets & Trientine Hydrochloride Capsules - 30/04/2019
Zydus and SIFI from Italy announce marketing alliance to launch Innovative Intraocular Lenses in India - 30/04/2019
Zydus receives final approval from the USFDA for Leflunomide Tablets USP - 25/04/2019
Zydus receives final approval from the USFDA for Acetazolamide for Injection - 17/04/2019
Press Release Phase 3 Trial of Desidustat in Chronic Kidney Disease - 17/04/2019
Zydus receives tentative approval from the USFDA for Lacosamide Tablets - 08/04/2019
Zydus receives tentative approval from the USFDA for Tofacitinib Tablets - 06/04/2019
Zydus receives tentative approval from the USFDA for Mirabegron Extended-Release Tablets - 02/04/2019
Zydus receives final approval from the USFDA for Ambrisentan Tablets - 29/03/2019
Zydus scores with the Day 1 launch of Tadalafil Tablets in the US - 27/03/2019
Zydus receives final approval from the USFDA for Lurasidone Hydrochloride Tablets - 22/03/2019
Zydus receives final approval from the USFDA for Acyclovir Ointment - 19/03/2019
Zydus receives final approval from the USFDA for Valsartan and Hydrochlorothiazide Tablets - 16/03/2019
Zydus receives tentative approval from the USFDA for Sitagliptin and Metformin Hydrochloride Extended-Release Tablets - 14/03/2019
Zydus receives final approval from the USFDA for Potassium Chloride Extended-Release Capsules USP - 13/03/2019
Zydus Receives final Approval from the USFDA for Atenolol and Chlorthalidone Tablets USP - 12/03/2019
Zydus receives USFDA approval for its first transdermal product, Rivastigmine Transdermal System - 05/03/2019
Zydus receives final approvals from the USFDA for Phytonadione Tablets and Colchicine Tablets - 21/02/2019
Zydus receives final approval from the USFDA for Triamterene and Hydrochlorothiazide Capsules USP - 13/02/2019
Zydus Cadila - 11/02/2019
Zydus receives final approval from the USFDA for Carbamazepine Extended-Release Tablets USP - 08/02/2019
Zydus Cadilas EBIDTA up by 22% in Q3 on a sequential basis - 07/02/2019
Zydus Wellness registers consolidated income from operations of Rs.1454 million in Q3 - 06/02/2019
Zydus Wellness completes acquisition of Heinz India - 30/01/2019
Meeting of Board of Directors / Closure of Trading Window - 24/01/2019
Zydus Receives Tentative Approval from the USFDA for Esomeprazole Magnesium Delayed-Release Capsules USP - 21/01/2019
Zydus Receives Final Approval from The USFDA for Acetazolamide ER Capsules - 17/01/2019
Zydus to Launch Novel Biologic for Rabies - 12/01/2019
Zydus receives final approval from the USFDA for Clobetasol Propionate Lotion - 08/01/2019
Zydus receives final approval from the USFDA for Clindamycin Phosphate and Benzoyl Peroxide Gel - 29/12/2018
Zydus receives approvals from the USFDA for Doxycycline Hyclate Delayed-Release Tablets and Febuxostat Tablets - 24/12/2018
Zydus receives approvals from the USFDA for Albendazole Tablets and Pregabalin Capsules - 15/12/2018
Liva Pharmaceuticals receives approval from the USFDA for its supplemental abbreviated new drug application (sANDA), Ranitidine Injection USP - 11/12/2018
Zydus receives final approval from the USFDA for Teriflunomide Tablets - 01/12/2018
Zydus receives approvals from the USFDA for Lansoprazole Tablets and Linagliptin tablets - 29/11/2018
Zydus receives final approval from the USFDA for Baclofen Tablets - 27/11/2018
Zydus receives approvals from the USFDA for Atorvastatin Calcium Tablets and Dimethyl Fumarate Delayed-Release Capsules - 22/11/2018
Zydus receives tentative approval from the USFDA for Deferasirox Tablets - 20/11/2018
Zydus receives final approval from the USFDA for Abacavir & Lamivudine Tablets and Fondaparinux Sodium Injection - 16/11/2018
Zydus receives final approval from the USFDA for Arsenic Trioxide Injection - 14/11/2018
Zydus receives final approval from the USFDA for Nystatin and Triamcinolone Acetonide Ointment USP - 12/11/2018
Zydus receives final approval from the USFDA for Vardenafil Hydrochloride tablets and Ursodiol tablets - 01/11/2018
Zydus receives final approval from the USFDA for Clobazam Tablets - 23/10/2018
Zydus receives tentative approval from the USFDA for Colchicine Tablets - 18/10/2018
Zydus receives final approval from the USFDA for Clobetasol Propionate Cream - 17/10/2018
Zydus receives tentative approval from the USFDA for Linagliptin and Metformin Hydrochloride Tablets - 12/10/2018
Zydus receives final approval from the USFDA for Exemestane Tablets - 05/10/2018
Zydus receives final approval from the USFDA for Risedronate Sodium Delayed-Release Tablets - 13/09/2018
Zydus receives tentative approval from the USFDA for Sitagliptin Tablets - 11/09/2018
Zydus receives final approval from the USFDA for two products, Gemfibrozil Tablets USP and Aripiprazole Orally Disintegrating Tablets USP - 30/08/2018
test - 30/08/2018
Cadila Healthcares Biologics manufacturing facility successfully completes USFDA inspection - 24/08/2018
Cadila Healthcare acquires 51% stake in Windlas Healthcare - 13/08/2018
Zydus Cadilas Net Profit up by 233% in Q1 - 13/08/2018
Zydus Wellness Consolidated Net Profit* up by 61.7% in Q1 - 03/08/2018
Zydus receives final approval from the USFDA for Azithromycin for Oral Suspension USP - 01/08/2018
Zydus receives tentative approval from the USFDA for Vardenafil Hydrochloride Tablets USP - 30/07/2018
Zydus receives final approval from the USFDA for Acetylcysteine Injection - 21/07/2018
Zydus receives final approval from the USFDA for Spironolactone Tablets USP - 20/07/2018
Zydus receives final approval from the USFDA for Piroxicam Capsules USP - 19/07/2018
Zydus receives four consecutive ANDA approvals from the USFDA - 18/07/2018
Zydus receives final approval from the USFDA for Clindamycin Phosphate Topical Solution USP - 17/07/2018
Zydus Hospira JV receives EIR Report for its Manufacturing Facility at Ahmedabad - 12/07/2018
Zydus receives final approval from the USFDA for Zolmitriptan Tablets USP - 12/07/2018
Zydus receives tentative approval from the USFDA for Deferasirox Tablets for Oral Suspension - 07/07/2018
CSIR-IMTECH in partnership with Zydus Cadila for development of newer drugs for drug-resistant infectious diseases - 05/07/2018
CSIR-IMTECH in partnership with Zydus Cadila for development of newer drugs for drug-resistant infectious diseases - 03/07/2018
Zydus receives final approval from the USFDA for Triamterene and Hydrochlorothiazide Tablets USP - 30/06/2018
Zydus receives tentative approval from the USFDA for Tadalafil Tablets USP - 19/06/2018
Zydus receives final approval from the USFDA for Doxycycline Hyclate Capsules USP - 02/06/2018
Zydus receives final approval from the USFDA for Nystatin Ointment USP and Omeprazole and Sodium Bicarbonate Capsules - 28/05/2018
Zydus receives final approval from the USFDA for Dutasteride and Tamsulosin Hydrochloride Capsules - 25/05/2018
Press release CHL Q4 and annual 2018 final - 25/05/2018
Zydus Wellness Consolidated Net Profit up by 22 % in Q4 - 24/05/2018
Zydus receives final approval from the USFDA for Carbidopa Tablets - 10/05/2018
Zydus receives final approval from the USFDA for Bumetanide Tablets USP - 02/05/2018
Zydus receives final approval from the USFDA for Methylprednisolone Tablets USP and Cinacalcet Hydrochloride Tablets - 25/04/2018
Zydus receives final approval from the USFDA for Diclofenac Sodium Topical Solution - 19/04/2018
Cadila Healthcares Topical facility successfully completes USFDA inspection - 28/03/2018
Zydus receives final approval from the USFDA for Metoprolol Succinate Extended-Release Tablets USP - 26/03/2018
Zydus receives final approval from the USFDA for Metoprolol Succinate Extended-Release Tablets USP - 17/03/2018
Zydus receives final approval from the USFDA for Tizanidine Tablets USP - 13/03/2018
Zydus partners with Medicure to launch its NDA Product, ZYPITAMAG - 08/03/2018
Zydus receives final approval from the USFDA for Dexmedetomidine Hydrochloride Injection - 28/02/2018
Cadila Healthcares Moraiya facility successfully completes USFDA inspection - 09/02/2018
Zydus Cadilas EBIDTA up by 108% in Q3 - 08/02/2018
Zydus Wellness Consolidated Net profit up by 43.8% in Q3 - 07/02/2018
Zydus receives final approval from the USFDA for Valacyclovir Tablets USP - 30/12/2017
Zydus receives final approval from the USFDA for Clomipramine Hydrochloride Capsules USP - 29/12/2017
Zydus receives final approval from the USFDA for Nifedipine Extended-Release Tablets USP - 21/12/2017
Zydus receives final approval from the USFDA for Pramipexole Dihydrochloride Extended-Release Tablets and Nitrofurantoin Capsules USP (macrocrystals) - 08/12/2017
Zydus receives final approval from the USFDA for Clozapine Tablets USP - 01/12/2017
Zydus receives final approval from the USFDA for Valacyclovir Tablets USP - 29/11/2017
Zydus receives final approval from the USFDA for Candesartan Cilexetil and Hydrochlorothiazide Tablets - 29/11/2017
New diagnostic kits developed to detect rare and neglected infectious diseases - 27/11/2017
Zydus receives final approval from the USFDA for Topiramate Extended-Release Capsules - 24/11/2017
Zydus receives approval from the USFDA for Minocycline Hydrochloride Extended-Release Tablets - 23/11/2017
Zydus receives tentative approval from the USFDA for Tadalafil Tablets USP - 20/11/2017
Zydus oral anemia developmental candidate, ZYAN1 named as Desidustat by WHO - 18/11/2017
Zydus receives final approval from the USFDA for Ethacrynate Sodium for Injection USP - 14/11/2017
Zydus Cadilas EBIDTA up by 68% in Q2 - 31/10/2017
Zydus Wellness Consolidated Net profit up by 13% in Q2 - 30/10/2017
Zydus announces regulatory approval of Lipaglyn (Saroglitazar Magnesium) in Mexico - 28/10/2017
Zydus Nesher Pharmaceuticals gets USFDA final approval for Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets - 14/10/2017
Zydus receives final approval from the USFDA for Doxycycline Hyclate Tablets USP - 12/10/2017
Zydus receives final approval from the USFDA for Clobetasol Propionate Ointment USP - 07/10/2017
Zydus receives final approval from the USFDA for Tamoxifen Citrate Tablets USP - 06/10/2017
Zydus receives final approval from the USFDA for Allopurinol Tablets USP - 05/10/2017
Zydus receives final approval from the USFDA for Desvenlafaxine Extended-Release Tablets - 04/10/2017
Zydus receives final approval from the USFDA for Amitriptyline Hydrochloride Tablets USP - 30/09/2017
Zydus receives final approval from the USFDA for Dutasteride Capsules - 29/09/2017
Zydus receives final approval from the USFDA for Desmopressin Nasal Spray Solution USP - 27/09/2017
Zydus receives final approval from the USFDA for Desmopressin Nasal Spray Solution USP - 23/09/2017
Zydus receives final approval from the USFDA for Doxycycline for Injection USP - 21/09/2017
Zydus receives final approval from the USFDA for Doxycycline Tablets USP - 20/09/2017
Zydus receives final approval from the USFDA for Indomethacin Extended-Release Capsules USP - 19/09/2017
Zydus receives final approval from the USFDA for Amlodipine and Olmesartan Medoxomil Tablets - 16/09/2017
Zydus receives final approval from the USFDA for Itraconazol Capsule 100 mg - 15/09/2017
Zydus receives final approval from the USFDA for Desoximetasone Ointment and Labetalol Hydrochloride Tablets - 07/09/2017
Zydus and Pharm Aid Ltd., enter into an exclusive agreement for vaccine technology in Russia - 02/09/2017
Zydus Nesher Pharmaceuticals gets USFDA final approval for Oseltamivir Powder for Oral Suspension - 01/09/2017
Zydus receives two product approvals from the USFDA - 30/08/2017
Cadila Healthcares Moraiya facility successfully completes USFDA inspection - 29/08/2017
Zydus receives final approval from the USFDA for Mycophenolate Mofetil for Injection USP - 24/08/2017
Zydus receives final approval from the USFDA for Donepezil Hydrochloride Tablets - 23/08/2017
Zydus receives final approval from the USFDA for Aspirin and Extended-Release Dipyridamole Capsules - 22/08/2017
Zydus receives EIR Report for Manufacturing Facility at the Pharma SEZ at Ahmedabad - 17/08/2017
Zydus receives final approval from the USFDA for Candesartan Cilexetil Tablets - 16/08/2017
Zydus receives final approval from the USFDA for Ziprasidone Hydrochloride Capsules - 14/08/2017
Zydus receives final approval from the USFDA for Pindolol Tablets USP - 11/08/2017
Zydus receives final approval from the USFDA for Telmisartan and Hydrochlorothiazide Tablets - 10/08/2017
Zydus receives final approval from the USFDA for Tiadylt ER Capsules and Azelastine Hydrochloride Nasal Spray - 09/08/2017
Zydus announces settlement with Aptalis on CANASA (mesalamine suppository, 1 g) - 08/08/2017
Zydus receives tentative approval from the USFDA for Mesalamine Suppositories for rectal use - 05/08/2017
Zydus Wellness Consolidated Net Profit up by 14.7% in Q1 - 01/08/2017
Zydus receives final approval from the USFDA for Diltiazem Hydrochloride Extended-Release Capsules USP - 25/07/2017
Zydus receives final approval from the USFDA for Memantine Hydrochloride Extended-Release Capsules - 19/07/2017
Zydus receives tentative approval from the USFDA for Abacavir and Lamivudine Tablets USP - 19/07/2017
Zydus receives final approval from the USFDA for Temozolomide Capsules and Nadolol Tablets USP - 14/07/2017
Zydus receives final approval from USFDA for Mesalamine Delayed-Release Tablets, 800 mg - 12/07/2017
Zydus launches Mesalamine Delayed Release Tablets in the US - 08/07/2017
Zydus receives final approval from the USFDA for Tranexamic Acid Injection - 05/07/2017
Zydus receives Tentative Approval from the USFDA for Fingolimod Capsules - 05/07/2017
Zydus receives final approval from the USFDA for Memantine Hydrochloride Tablets - 04/07/2017
Zydus receives Final Approval from the USFDA for Doxazosin Tablets - 30/06/2017
Phibro Animal Health Corporation and Zydus Cadila announce their intention to license Phibros Poultry Vaccine Technologies - 29/06/2017
Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD - 28/06/2017
Zydus receives tentative approval from the USFDA for Sitagliptin and Metformin Hydrochloride Tablets - 27/06/2017
Zydus receives final approval from the USFDA for Phentermine Hydrochloride Orally Disintegrating Tablets - 21/06/2017
Zydus Nesher Pharmaceuticals gets USFDA final approval for Dextroamphetamine Sulfate Extended-Release Capsules - 20/06/2017
Zydus receives final approval from the USFDA for Oxybutynin Chloride Extended-Release Tablets - 19/06/2017
Zydus receives final approval from the USFDA for Entecavir Tablets - 15/06/2017
Zydus receives EIR Report for Moraiya Manufacturing Facility - 13/06/2017
Zydus receives final approval from the USFDA for Diflunisal Tablets - 10/06/2017
Zydus receives final approval from the USFDA for Eletriptan Hydrobromide Tablets - 07/06/2017
Zydus receives final approval from the USFDA for Acyclovir for Injection USP - 05/06/2017
Zydus receives final approval from the USFDA for Ezetimibe Tablets USP - 02/06/2017
Zydus Nesher Pharmaceuticals gets USFDA final approval for Nystatin Topical Powder - 31/05/2017
Zydus Cadila gets USFDA final approval for Mesalamine Delayed-Release Tablets USP, 1.2 g - 27/05/2017
Zydus receives final approval from the USFDA for Mirtazapine Orally Disintegrating Tablets USP - 27/05/2017
Zydus Moraiya Plant receives first product approval, post successful USFDA Audit - 27/05/2017
Zydus receives final approval from the USFDA for Felbamate Tablets USP - 23/05/2017
Zydus Cadila, the first to launch revolutionary anti-obesity drug Slimona in India - 15/05/2017
Zydus receives final approval from the USFDA for Acamprosate Calcium Delayed-Release Tablets - 10/05/2017
Zydus Wellness Consolidated Total Income from Operations up by 14.4% in Q4 - 05/05/2017
Zydus Cadila registers Net Profit of Rs. 1488 crores in FY 17 - 26/04/2017
Zydus receives final approval from the USFDA for Cholestyramine for Oral Suspension USP - 26/04/2017
Zydus receives final approval from the USFDA for Cyproheptadine Hydrochloride tablets USP - 25/04/2017
Zydus receives final approval from the USFDA for Olmesartan Medoxomil Tablets - 25/04/2017
Zydus Cadila receives final approval from the USFDA for Tizanidine Hydrochloride Capsules - 08/03/2017
Zydus wins Federal Circuit Appeal in generic version of Lialda (Mesalamine) - 08/03/2017
Zydus receives final approval from the USFDA for Budesonide Capsules.pdf - 07/03/2017
Zydus announces settlement with Supernus on Trokendi XR (topiramate) extended-release capsules - 07/03/2017
Zydus Nesher Pharmaceuticals receives final approval from the USFDA for Oseltamivir Phosphate Capsules - 27/02/2017
Zydus Cadila to launch Indias 1st Tetravalent Inactivated Influenza vaccine VaxiFlu 4 - 24/02/2017
Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis (PBC) - 23/02/2017
Zydus receives final approval from the USFDA for Fluconazole Tablets USP and Clobetasol Propionate Spray - 17/02/2017
The Ramanbhai Foundation 8th International Research Symposium on Advances in New Drug Discovery and Development gets underway - 02/02/2017
Zydus Wellness registers consolidated total income from operations of Rs. 1118 mn in Q3 - 30/01/2017
Zydus Cadila acquires Sentynl Therapeutics Inc., a US based specialty pharmaceutical company - 19/01/2017
Zydus receives final approval from the USFDA for Methotrexate Tablets USP - 18/01/2017
Zydus announces settlement with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd. on Livalo (pitavastatin calcium) tablets - 17/01/2017
Zydus announces settlement with Upsher-Smith Laboratories, Inc. on Qudexy XR (topiramate) extended-release capsules - 13/01/2017
Zydus acquires six brands from MSD - 28/12/2016
Zydus Announces Settlement of a DELZICOL - 03/12/2016
Zydus receives final approval from the USFDA for Metronidazole Tablets - 21/11/2016
Zydus To Present New Scientific Data Of Investigational Saroglitazar - 31/10/2016
Zydus Wellness registers a Net Profit of Rs. 321 mn in Q2 - 25/10/2016
Zydus and Medicines for Malaria Venture Sign Agreement to Develop Potential New Antimalarial Drug - 30/09/2016
Zydus and Takeda enter into partnership to address emerging infectious diseases - 20/09/2016
Zydus strengthens its derma portfolio with the brand acquisition of MELGAIN from Issar Pharma in India - 08/08/2016
Zydus receives final approval from the USFDA for Nateglinide Tablets USP - 11/07/2016
Zydus enters into a sub-licensing agreement with The Medicines Patent Pool for Hepatitis C Medicine, daclatasvir - 07/07/2016
Zydus acquires two ANDAs from Teva, strengthens its US portfolio - 20/06/2016
Zydus Cadila and Eczaciba a Turkish Healthcare Company, enter into a strategic collaboration to market biosimilars in Turkey - 15/06/2016
New Scientific Data of Investigational LipaglynTM (Saroglitazar), And Real World Data in Patients will be featured at American Diabetes Association (ADA) 76th Scientific Sessions - 11/06/2016
Zydus receives approval from the USFDA to initiate Phase 2 clinical trials of Saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in USA. - 04/06/2016
Zydus receives final approval from the USFDA for Amantadine Hydrochloride Capsules - 01/06/2016
Zydus receives final approval from the USFDA for Voriconazole Tablets - 25/05/2016
Two presentations highlighting Zydus drug, Lipaglyn will be featured at the AACE Annual meeting - 24/05/2016
Zydus Cadilas Net Profit up by 32% to Rs. 1523 crore - 13/05/2016
Zydus Wellness Consolidated Net Profit up by 10% in Q4 - 12/05/2016
Zydus receives final approval from the USFDA for Glyburide Tablets - 11/05/2016
Zydus expands animal health business with a strategic acquisition - 01/05/2016
Zydus receives final approval from the USFDA for Carboplatin Injection - 01/04/2016
Zydus Nesher Pharmaceuticals receives its first ANDA approval for Dextroamphetamine IR Tabs - 30/03/2016
Zydus receives final approval from the USFDA for Acyclovir Capsules USP - 29/03/2016
Zydus acquires the gastro therapy Actibile from Albert David Limited Strengthens its presence in the gastroenterology segment - 28/03/2016
Zydus receives tentative approval from the USFDA for Clofarabine Injection - 09/03/2016
Zydus receives final approval from the USFDA for Glyburide and Metformin Hcl Tablets USP - 01/03/2016
Zydus to commence supplies to the US market from its formulation manufacturing facility at SEZ - 19/02/2016
Zydus Cadila net profit up by 38% in Q3 - 05/02/2016
Zydus Wellness Consolidated Net Profit up by 12.5% in Q3 - 04/02/2016
Zydus launches Tenglyn, the most affordable gliptin for diabetics in India - 20/11/2015
Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA - 18/11/2015
Zydus Cadilas Net Profit up by 41% in Q2 - 22/10/2015
Zydus Wellness registers a Net Profit of Rs. 291 mn in Q2 - 21/10/2015
Zydus Cadila Q1 Net Profit up by 47% - 12/08/2015
Zydus receives final approval for Amiloride Hcl Tablets - 11/08/2015
Zydus Wellness consolidated net profit up by 14.5% in Q1 - 29/07/2015
Zydus receives market authorisation for Morphine Sulfate ER Tablets - 01/07/2015
Zydus receives final approval for Pyridostigmine Bromide Tablets - 24/06/2015
Zydus to present new scientific data on Lipaglyn (Saroglitazar), and real world data in patients with Type 2 Diabetes at the American Diabetes Association 75th Scientific Sessions in Boston, USA - 06/06/2015
Zydus Cadilas Net Profit soars to Rs. 1151 crore - 15/05/2015
Zydus to present New Clinical Data on Lipaglyn at the American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress in Nashville, TN, USA - 12/05/2015
Zydus Group to donate USD 240,000 to The National Institutes of Health, USA for advancing leishmaniasis research - 18/04/2015
Zydus launches SoviHep - the breakthrough therapy for Hepatitis C in alliance with Gilead Sciences - 17/03/2015
Zydus completes single rising dose Phase I studies for its oral HIF inhibitor, ZYAN1 for treating Anemia and initiates multiple dosing studies - 16/02/2015
Zydus Cadila Net Profit up by 52% in Q3 - 10/02/2015
Zydus announces data presentations on Saroglitazar for treating NASH, a liver disease, at the 2015 Keystone Symposia Conference on Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD) in British Columbia, Canada - 06/02/2015
The Ramanbhai Foundation 7th International Research Symposium Advances in New Drug Discovery and Development gets underway - 02/02/2015
Zydus begins Phase - III study of Saroglitazar in NASH, a liver disease caused by obesity diabetes and lipid disorders - 09/01/2015
Zydus launches worlds first biosimilar of Adalimumab - 09/12/2014
Zydus Cadilas Net Profit up by 52% in Q2 - 06/11/2014
Zydus receives tentative approval for Glipizide ER tablets - 16/09/2014
ZYDUS AND GILEAD ENTER INTO A GENERIC LICENSING AGREEMENT TO MANUFACTURE BREAKTHROUGH TREATMENT FOR HEPATITIS C - 15/09/2014
Zydus receives final approval for Telmisartan Tablets - 29/08/2014
Zydus receives final approval for Acyclovir Tablets - 20/08/2014
Zydus receives final approval for Potassium Citrate ER Tablets - 07/08/2014
Zydus Cadila Q1 Net profit up by 23% - 30/07/2014
Zydus announces data presentations on ZYDPLA1 A once-weekly small molecule DPP-IV inhibitor for treating diabetes, at the ENDO conference in Chicago, Illinois, USA. - 09/06/2014
Zydus explores newer treatment options with its breakthrough drug, LipaglynTM - 29/05/2014
Zydus Cadilas Net Profit zooms to Rs. 804 crore - 16/05/2014
Cadila Healthcare Limited Announces Settlement with Depomed on Gralise - 15/04/2014
Zydus receives final approval for Clonidine Hcl Injection - 14/02/2014
Zydus Cadila Net Profit up by 82% in Q3 - 07/02/2014
Zydus receives final approval for Sirolimus Tablets with 180 days of marketing exclusivity - 09/01/2014
Zydus Pharmaceuticals (USA) Inc agreement with Warner Chilcott Company LLC - 11/12/2013
Zydus Cadila registers 94% increase in Net Profit in Q2 - 31/10/2013
Zydus announces US FDA approval for initiating Phase I clinical trials of ZYDPLA1 - a novel next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes - 23/10/2013
Zydus and Pieris Sign Broad Co-Development Alliance for Novel Anticalin Therapeutics - 16/10/2013
Zydus receives final approval for Lansoprazole DR Capsules - 21/08/2013
Zydus and IDRI sign agreement for the development of IDRIs Vaccine Candidate for Visceral Leishmaniasis (Kala-Azar) - 25/07/2013
Zydus Cadilas Net Profit up by 54% in Q4 - 30/05/2013
Zydus scores with the Day 1 launch of Zolmitriptan in the US - 13/05/2013
Zydus Wellness Net Profit up by 43.5% in FY 13 - 13/05/2013
Zydus Cadila receives tentative approval for Amlodipine Besylate and Benazepril Hydrochloride Capsules - 30/03/2013
Zydus Cadila receives tentative approval for Doxepin Hcl tablets - 27/02/2013
Zydus receives final approval for Ranitidine Hcl injection - 15/02/2013
Zydus receives final approval for Pioglitazone HCl tablets - 14/02/2013
Zydus receives approval for Irbesartan Tablets - 29/09/2012
Zydus Cadila registers 30% growth in sales in Q1 - 06/08/2012
Zydus Wellness Net Profit up by 59.6% in Q1 - 27/07/2012
Cadila Healthcare enters into a settlement and license agreement with Somaxon for Silenor - 19/07/2012
Zydus Urosciences launches Udenafil a next gen therapy for erectile dysfunction for the first time in India - 18/07/2012
Zydus Cadila Total Income up by 20% in Q3 - 07/02/2012
Zydus acquires 100% stake in Mumbai-based Biochem - 21/12/2011
Zydus Cadila expands the Scientific Advisory Board at Zydus Research Centre - 15/12/2011
Zydus Cadila acquires German company, Bremer Pharma GmbH, from ICICI Venture, gains global footprint in animal healthcare business - 27/07/2011
Zydus Baddi plant gets USFDA approval - 25/07/2011
Zydus Cadila Q1 Net profit reaches Rs. 230 crore - 19/07/2011
Zydus US subsidiary enters into an asset purchase agreement in the US - 17/06/2011
Zydus Cadilas Net Profit zooms by 41% in FY 11 - 06/05/2011
Zydus Wellness Net Profit jumps by 31.4% in FY 11 - 05/05/2011
Zydus IND application of ZYGK1 for treating diabetes receives USFDA approval - 07/04/2011
Zydus Cadila joins the billion dollar league - 01/04/2011
Bayer and Zydus join hands to set up a new pharmaceuticals Joint Venture in India - 28/01/2011
Zydus Cadilas Net Profit up by 25% in Q3 - 18/01/2011
Zydus Wellness Net Profit up by 36.6% in Q3 - 17/01/2011
Zydus Cadila registers 30% increase in Net Profit in Q2 - 19/10/2010
Zydus Wellness Net Profit up by 58% in Q2 - 18/10/2010
Zydus Cadila launches Pramipexole Tablets in the US market - 14/10/2010
Zydus Cadila receives USFDA approval for Losartan Potassium tablets and Losartan Potassium + Hydrochlorothiazide tablets - 07/10/2010
Zydus Nycomed commissions the newly expanded API manufacturing facility at Navi Mumbai - 29/09/2010
Zydus Cadila Q1 Net profit up by 60% - 27/07/2010
Zydus Wellness Net Profit up by 52.4% in Q1 - 16/07/2010
Zydus Cadila launches Anastrazole Tablets in the US market on receiving USFDA approval - 29/06/2010
Zydus novel orally administered GLP-1 agonist -ZYOG1 to treat Diabetes and Obesity enters Phase I clinical trial - 21/06/2010
Vaxiflu-S - Indias first H1N1 vaccine is launched - 03/06/2010
Zydus Cadila to launch Indias 1st H1N1 vaccine - 12/05/2010
Zydus Cadila and Abbott sign pact for commercialising branded generics in emerging markets - 11/05/2010
Zydus Cadilas Net Profit zooms by 67% in FY 10 - 29/04/2010
Zydus receives approval for Tamsulosin capsules - 28/04/2010
CHL announces Bonus Shares in the ratio of 1:2 - 25/02/2010
Mr. Pankaj R. Patel, CMD - Zydus Cadila, wins E&Y Entrepreneur of the Year - Healthcare and Life Sciences Award 2009 - 17/02/2010
Zydus Cadilas Net Profit up by 114% in Q3 - 25/01/2010
Zydus Cadila to start clinical trials of H1N1 vaccine - 04/01/2010
Simayla becomes a 100% subsidiary of the Zydus Group - 31/12/2009
Zydus Cadila registers 39% increase in Net Profit in Q2 - 27/10/2009
Zydus Cadila Q1 Net profit surges by 39% - 27/07/2009
Zydus files IND application with the DCGI for ZYD1 - a novel candidate to treat Diabetes and Obesity - 04/06/2009
Zydus receives approval for Mycophenolate Mofetil tablets and capsules - 05/05/2009
Zydus Cadilas Total Income up by whopping 26% in FY 09 - 28/04/2009
Zydus files IND application with the USFDA for ZYT1 a novel candidate to treat dyslipidemia - 02/04/2009
Zydus receives final approval for Topiramate Tablets - 31/03/2009
Zydus Cadila announces research collaboration to discover and develop new cardiovascular medicines - 30/03/2009
Zydus Research Centre Receives AAALAC Accreditation - 04/03/2009
New Approvals strengthen Zydus US product basket - 29/01/2009
Zydus Cadilas Total Income up by 31% in Q3 - 27/01/2009
Zydus Cadila acquires Etna Biotech, a subsidiary of Crucell N.V. - 11/11/2008
Zydus Cadila registers 33% increase in Operating Net Profit in Q2 - 22/10/2008
Zydus receives approval for Risperidone Tablets - 20/10/2008
Zydus files IND application for ZYT1 a novel candidate to treat dyslipidemia - 16/10/2008
Zydus Cadila becomes the 1st Indian Pharma company to receive WHO accreditation for Rabies vaccine - 14/10/2008
Zydus receives USFDA approval for Ramipril Capsules - 04/09/2008
Zydus and WHO to develop next-generation biologicals to fight rabies - 12/08/2008
Zydus receives approval for Bromocriptine Mesylate Capsules - 01/08/2008
Zydus Cadila Q1 Net profit up by 21% - 29/07/2008
Cadila Healthcare to restructure its consumer business and create a single listed entity - 04/07/2008
Zydus scores with first day launch of Venlafaxine Hydrochloride in the US - 16/06/2008
Zydus acquires majority stake in Simayla Pharmaceuticals of South Africa - 09/06/2008
Zydus Cadila enters Spain, acquires Laboratorios Combix - 30/05/2008
Zydus Cadila to market Benazepril in the US - 26/05/2008
New Product Approvals for Zydus Cadila from USFDA - 15/05/2008
Zydus Cadilas Net Sales up by whopping 27% in FY 08 - 29/04/2008
Zydus and Nycomed expand scope of JV to create an API manufacturing hub for global supplies - 11/03/2008
Zydus Cadila firms up presence in Oncology segment with Nudoxa - 15/02/2008
Zydus Cadila and Karo Bio of Sweden sign research agreement for a novel drug to treat inflammatory diseases - 04/02/2008
Zydus Cadilas Income up by 22.7% in Q3 - 31/01/2008
Zydus Cadila and Prolong Pharmaceuticals ink pact for collaboration in Drug Discovery and Development - 24/01/2008
CRISIL reaffirms CADILA HEALTHCARE LIMITEDs ratings - 19/12/2007
Zydus Cadila registers 28% Income growth in Q2 - 26/10/2007
Zydus Cadila receives USFDA approval for Hydroxychloroquine Sulfate Tablets - 25/09/2007
Zydus Cadila receives USFDA approval for Carvedilol Tablets Launches product on the very same day - 06/09/2007
Zydus Cadila files its 5th IND ZYH7 - a novel drug candidate for treating dyslipidemia and metabolic disorders - 30/08/2007
Zydus Cadila Q1 Net profit up by 27% - 31/07/2007
Zydus Cadila acquires Brazilian company Nikkho - 25/06/2007
Zydus Cadila receives tentative approval for Topiramate tablets - 06/06/2007
Zydus Cadila buys out JV stake in Sarabhai Zydus Animal Health Ltd - 14/05/2007
Zydus Cadilas Net Profit up by whopping 53% in FY 07 - 26/04/2007
Zydus receives tentative approval for Losartan Potassium tablets - 20/04/2007
Zydus Cadila acquires Nippon Universal, strengthens its presence in Japan - 19/04/2007
New Approvals strengthen Zydus US product basket - 17/03/2007
Zydus Cadila acquires Liva Healthcare, enters the 1500 cr. derma market - 16/03/2007
Zydus Cadila receives USFDA approval for Paroxetine Tablets - 12/03/2007
Mr. P. R. Joshi, President Group HR, Zydus Cadila receives HR Leadership Award at the Asia Pacific HRM Congress - 05/02/2007
Zydus Research Centre to host International Symposium on Advances in Diabetes Therapy - 25/01/2007
Zydus Research Centre to host International Symposium on Advances in Diabetes Therapy - 25/01/2007
Zydus Cadila Q3 Net profit up by 66.4% - 22/01/2007
Zydus Cadila Q3 Net profit up by 66.4% - 22/01/2007
Update on Disinvestment of equity stake of Mylab Discovery Solutions Private Limited by Zydus Animal Health and Investments Limited, a Wholly Owned Subsidiary Company 17-Dec-2024
Disinvestment of equity stake of Mylab Discovery Solutions Private Limited by Zydus Animal Health and Investments Limited, a Wholly Owned Subsidiary Company 16-Dec-2024
Demand Notice from GST Department 28-Nov-2024
Receipt of a Certificate of Merger approving merger of Nesher Pharmaceuticals (USA) LLC USA, (“Nesher”) with Zydus Pharmaceuticals USA Inc., USA (“ZPUI”) 17-Sep-2024
Order from GST Department 29-Sep-2024
Acquisition of API Business 17-Sep-2024
Order from GST Department 07-Sep-2024
Clarification w.r.t. intimation dated August 30, 2024, regarding receipt of warning letter from USFDA 03-Sep-2024
Order-In-Original from Sales Tax Officer, Delhi 01-Sep-2024
Order-In-Original from Superintendent, Jurisdiction: CUTTACK IV RANGE: CUTTACK I, Odisha 30-Aug-2024
Order-In-Original from Deputy Commissioner ST, Special Circle-VJA1: Vijayawada I: Andhra Pradesh 30-Aug-2024
Order-In-Original from Deputy Commissioner of State Tax, Durg-1, Chattisgarh 30-Aug-2024
Closing of acquisition of shares of Sterling Biotech Limited 30-Aug-2024
Order-In-Original from Assistant Commissioner, Siliguri, West Bengal 29-Aug-2024
Order-In-Original from Joint Commissioner, Corporate Circle, Ghaziabad-I, Uttar Pradesh 28-Aug-2024
Clarification on market rumour in Mainstream Media 26-Aug-2024
Acquisition of equity shares of Sterling Biotech Limited 23-Aug-2024
Order-In-Original from Deputy Commissioner DGSTO-6, Bengaluru-Karnataka 20-Aug-2024
Order-In-Original from Commercial Tax Officer, Ward-8, Chandigarh 20-Aug-2024
Order-In-Original from Office of Deputy Commissioner, Ghaziabad 13-Aug-2024
Change in Director | 09-08-2024
Order-in-Original from GST 09-Aug-2024
Order-In-Original from Superintendent I-A Range, Guwahati-D, Assam 08-Aug-2024
Receipt of an order from State Tax Officer, M S Kutch, Div-12, Gandhidham 26-Jul-2024
Received report from the USFDA for its injectable manufacturing facility at Jarod, near Vadodara
Demand Order from GST
Rectification Order from CPC-Income Tax Department 01-Jul-2024
Appointment of Director | 17-05-2024
Board Meeting - Disclosure under SEBI (LODR) Regulations, 2015 | 17-05-2024
Update on Sale of stake in JV Company 06-May-2024
Acquisition of worldwide proprietary rights to Zokinvy® by Sentynl Therapeutics Inc., USA, a wholly owned subsidiary of Zydus Lifesciences Limited 04-May-2024
Sale of stake in JV Company 02-May-2024
Demand order from Office of the State Taxes Officer, Circle-L, State Jammu 30-Apr-2024_Revised
Demand order from Office of the Assistant Commissioner of State Tax, SAS Nagar (Mohali) 30-Apr-2024_Revised
Demand order from Deputy State Tax Officer 1, Thiruvanmiyur 30-Apr-2024
Demand order from Deputy Commissioner of State Tax, Durg, Chhattisgarh 01-May-2024
Demand order from Office of the State Taxes Officer, Circle-L, State Jammu 30-Apr-2024
Demand order from Office of the Assistant Commissioner of State Tax, SAS Nagar (Mohali) 30-Apr-2024
Demand order from Deputy Commissioner of State Tax, Patna West Circle, Patna 30-Apr-2024
Demand order from Assistant Commissioner of Revenue, Siliguri Charge, SGST 30-Apr-2024
Demand order from Deputy Commissioner, Secunderabad STU-1, Telangana 30-Apr-2024
Demand order from Office of Excise and Taxation Officer cum State Tax Officer, Mohali, State Punjab 29-Apr-2024
Demand order from Office of the Sales Tax Officer, Class-II, State Delhi 29-Apr-2024
Demand order from Office of the Deputy Commissioner, Ghaziabad-I, Uttar Pradesh 25-Apr-2024
MPS Compliance 23-Maar-2024
Demand order from Excise And Taxation Officer-cum-State Tax Officer, Punjab 12-Feb-2024
Incorporation of a WOS in UAE 22-Feb-2024
Demand notice from CGST 30-Jan-2024
Demand Notice from Stamp Authority 04-Jan-2024
Penalty under GST 03-Jan-2024 (2)
Penalty from GST 02-Jan-2024
Penalty under GST 03-Jan-2024 (1)
Penalty from GST 01-Jan-24
Penalty and Interest from VAT and CST 29-Dec-2023
Penalty from CGST and Excise 29-Dec-2023
Dissolution of ZNI 18-Dec-2023
Demand Notice from GST Department 13-Dec-2023
Demand Notice from GST Department 05-Dec-2023
Closing of Business Undertaking Transaction 08-Aug-2023
Change in Senior Management
Re-appointment of Director | 18-05-2023
Board Meeting - Disclosure under SEBI (LODR) Regulations, 2015 | 18-05-2023
Appointment of two independent directors | 29-Nov-2022
Acquisition of a business undertaking | 29-Nov-2022
Further investment in AMP | 02-Nov-2022
Further investment in AMP | 22-Sep-2022
Statutory Auditor Intimation | 10-Aug-2022
Investment in AMP | 16-March-2022
Reappointment of Sharvil Patel | 21-Jan-2022
Completion of disposal of Undertaking | 14-July-2021
Reappointment of Ganesh N. Nayak | 09-July-2021
Extention of JV agreement | 21-June-2021
Disposal of Animal Business | 12-May-2021
Extention of JV agreement | 05-May-2021
Reappointment of Director 05 February 2021
Change in interest in ABCD Technologies LLP | 30-04-2021
Acquisition of stake in Pharmarack | 01-04-2021
31-03-2021 | Acquisition of stake in AIOCD Pharmasofttech Awacs Private Limited
Change in interest in ABCD Technologies LLP | 31-03-2021
ABCD Technologies LLP | 25-03-2021
USFDA Inspection | 20-12-2019
Amalgamation of Subsidiaries | 02-12-2019
Acquisition of stake in ZTL | 13-11-2019
USFDA Inspection | 04-11-2019
Baddi EIR | 31-10-2019
EIR | 23-09-2019
Asset Purchase Agreement
USFDA Inspection
USFDA Inspection | 03-06-2019
USFDA Inspection | 03-05-2019
USFDA Inspection | 03-04-2019
USFDA Inspection | 27-03-2019
USFDA Inspection | 22-03-2019
Prequalification from WHO | 15-02-2019
